semaglutide news 2025 Market Size, Share & Trends Report, 2025-2035 Novo Nordisk study finds greater

A new, federally funded retrospective study led by Johns Hopkins Medicine strongly suggests that semaglutide and other GLP-1 RAs did not statistically change the risk of developing neovascular age-related macular degeneration (NVAMD) a fast-progressing, blinding condition that is caused by uncontrolled, abnormal blood vessel growth in the back of the eye in adults with type 2 diabetes without a prior history of GLP-1 use

10.1056/NEJMoa2111016 77 VincentiF.FervenzaF

Based on the review of all the diets, they all may have a role in MASLD, and they work by different metabolic mechanisms

The Bottom Line Semaglutide is used in different ways depending on the reason it is prescribed